

## Publikationen

Rühl M, **Johannsen M**, Atkinson J, Manski D, Sahin E, Somasundaram R, Riecken E.O., Schuppan D. Soluble Collagen VI Induces Tyrosine Phosphorylation of Paxillin and Focal Adhesion Kinase and Activates the MAP Kinase Erk2 in Fibroblasts. *Exp Cell Res* 1999; 250: 548-57

Rühl M, Sahin E, **Johannsen M**, Somasundaram R, Manski D, Riecken E O, Schuppan D. Soluble Collagen VI Drives Serum-starved Fibroblasts through S Phase and Prevents Apoptosis via Down regulation of BAX. *J Biol Chem* 1999; 274, 48: 34361-68.

**Johannsen M**, Rühl M, Manski D, Somasundaram R, Riecken EO, Schuppan D. Native Extraction of Phosphotyrosine-Containing Proteins: Requirement of Tyrosine Kinase Inhibitors to Obtain Specific Phosphorylation Signals. *Anal Biochem* 2000 Mar 15;279 (2): 242-5.

Jordan A, Scholz R, Maier-Hauff K, **Johannsen M**, Wust P, Nadobny J, Schirra H, Schmidt H, Deger S, Loening SA, Lanksch W, Felix R. Presentation of a new Magnetic Field Therapy System for the Treatment of Human Solid Tumors with Magnetic Fluid Hyperthermia. *J Magn Magn Mat* 2001; 225:118-126.

Lein, M, Jung, K, Ortel, B, Stephan, C, Rothaug, W, Juchem, R, **Johannsen M**, M, Deger, S, Schnorr, D, Loening, SA and Krell, H-W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. *Oncogene*, 21: 2089-2096, 2002.

Roigas J, Deger S, Taymoorian K, Wille A, **Johannsen M**, Türk I, Schnorr D, Loening SA. Effects of 13-cis retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma – results of a retrospective analysis. *Cancer Biother Radiopharm* 2003 Apr; 18(2): 157-63

**Johannsen M**, Wilke K, Schnorr D, Loening SA. Taxanes in the chemotherapy of hormone-refractory prostate carcinoma. *Der Urologe A* 2004; 43 (2): 160-167

**Johannsen M**, Jordan A, Scholz R, Lein M, Koch M, Deger D, Roigas J, Jung K and Loening SA. Evaluation of magnetic fluid hyperthermia (MFH) in a standard rat model of prostate cancer. *J Endourol*, 2004; 18 (5): 495-500

Jung M, Xu C, Spethmann J, **Johannsen M**, Deger S, Stephan C, Loening SA, Jung K. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeneys LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. *Eur Urol* 2003;44:8-16. *Eur Urol* 2004 Aug;46(2):271-2.

**Johannsen M**, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, Waldöfner N, Scholz R, Koch M, Lein M, Jung K, Loening SA. Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. *Prostate* 2005; Aug 1;64(3):283-92

**Johannsen M**, Sachs M, Roigas J, Hinke A, Staack A, Loening SA, Schnorr D, Wille AH. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. *Eur Urol* 2005 Aug;48(2):246-51

**Johannsen M**, Loening SA, Deger S. Re: Current status of local salvage therapies following radiation failure for prostate cancer. *J Urol* 2005 Sep;174(3):1152-3; author reply 1153

**Urologische  
Facharztpraxis  
PD Dr. Johannsen**

**Priv. Doz.  
Dr. med. Manfred Johannsen**  
(F.E.B.U.)

Facharzt für Urologie  
und Andrologie  
Medikamentöse Tumorthherapie

Carl-Schurz-Str. 31  
13597 Berlin  
Tel. 030 333 4030  
Fax 030 333 1783

[www.urologie-in-spandau.de](http://www.urologie-in-spandau.de)  
[info@urologie-in-spandau.de](mailto:info@urologie-in-spandau.de)

Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, **Johannsen M**, Lein M, Loening SA, Jung K, Staack A. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. *Oncol Rep* 2005 Sep;14(3):777-82

**Johannsen M**, Gneveckow U, Eckelt L, Feussner A, Waldöfner N, Scholz R, Deger S, Wust P, Loening SA, Jordan A. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. *Int J Hyperther* 2005 Nov;21(7):637-47.

May M, **Johannsen M**, Beutner S, Helke C, Braun KP, Lein M, Roigas J, Hoschke B. Laparoscopic Surgery versus Antegrade Scrotal Sclerotherapy: Retrospective Comparison of Two Different Approaches for Varicocele Treatment. *Eur Urol* 2006, Feb;49(2):384-7.

**Johannsen M**, Thiesen B, Gneveckow U, Taymoorian K, Waldöfner N, Scholz R, Deger S, Jung K, Loening SA, Jordan A. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. *Prostate* 2006, Jan 1;66(1):97-104.

Bhuvarahamurthy V, Kristiansen G, **Johannsen M**, Loening SA, Schnorr D, Jung K, Staack A. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9 and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. *Oncol Rep* 2006, May;15(5):1379-84.

Roigas J, **Johannsen M**, Ringsdorf M, Massenkeil G. Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma. *Exp Rev Anticancer Ther* 2006 Oct;6(10):1449-58.

Jordan A, Scholz R, Gneveckow U, Maier-Hauff K, **Johannsen M**, Wust P. MagForce® Nano-Krebstherapie. *Praxis der Naturwissenschaften* 2006;55:8-11.

Wust P, Gneveckow U, **Johannsen M**, Bohmer D, Henkel T, Kahmann F, Sehoul J, Felix R, Rieke J, Jordan A. Magnetic nanoparticles for interstitial thermotherapy – Feasibility, tolerance and achieved temperatures. *Int J Hyperther* 2006 Dec;22(8):673-85.

Beutner S, May M, Hoschke B, Helke C, Lein M, Roigas J, **Johannsen M**. Treatment of varicocele with reference to age: a retrospective comparison of three minimally invasive procedures. *Surg Endosc* 2007 Jan;21(1):61-5.

**Johannsen M**, Gneveckow U, Thiesen B, Taymoorian K, Cho CH, Waldöfner N, Scholz R, Jordan A, Loening SA, Wust P. Thermotherapy of Prostate Cancer Using Magnetic Nanoparticles: Feasibility, Imaging and Three-Dimensional Temperature Distribution. *Eur Urol* 2007 Dec;52(6):1653-61

**Johannsen M**, Gneveckow U, Taymoorian K, Thiesen B, Waldöfner N, Scholz R, Jung K, Jordan A, Wust P, Loening SA. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. *Int J Hyperther* 2007 May;23(3):315-23.

**Johannsen M**, Ringsdorf M, Römer A, Loening SA, Roigas J. Zytokinbasierte und molekulare Therapie des metastasierten Nierenzellkarzinoms – eine aktuelle Analyse. *Akt Urol* 2007 Jan;38(1):38-45.

**Priv. Doz.  
Dr. med. Manfred Johannsen**  
(F.E.B.U.)

Facharzt für Urologie  
und Andrologie  
Medikamentöse Tumorthherapie

Carl-Schurz-Str. 31  
13597 Berlin  
Tel. 030 333 4030  
Fax 030 333 1783

[www.urologie-in-spandau.de](http://www.urologie-in-spandau.de)  
[info@urologie-in-spandau.de](mailto:info@urologie-in-spandau.de)

**Johannsen M**, Roigas J, Loening SA. New Frontiers in Renal Cell Cancer. Eur Urol Suppl 2007 Vol. 6 (10), 601-602

Deger S, Wille A, Roigas J, Lein M, Giessing M, **Johannsen M**, Ebeling V, Loening SA, Bachmann A. Laparoscopic and Retroperitoneoscopic Radical Nephrectomy: Techniques and Outcome. Eur Urol Suppl 2007 Vol. 6 (10), 630-34

Wille AH, Deger S, Tüllmann M, Lau A, **Johannsen M**, Lein M, Loening SA, Roigas J. Laparoscopic Partial Nephrectomy in Renal Cell Cancer—Indications, Technique, and Outcome in 80 Patients. Eur Urol Suppl 2007 Vol. 6 (10), 635-40

Kloeters C, Mager A-K, **Johannsen M**, Ringsdorf M, Roemer A, Tuellmann M, Hamm B, Hein E, Rogalla P. Radiofrequency Ablation of Metastases from Renal Cell Carcinoma: Technique, Complications, and Midterm Outcome. Eur Urol Suppl 2007 Vol. 6 (10), 653-57

**Johannsen M**, Brinkmann OA, Bergmann L, Heinzer H, Steiner T, Ringsdorf M, Roemer A, Roigas J. The Role of Cytokine Therapy in Metastatic Renal Cell Cancer. Eur Urol Suppl 2007 Vol. 6 (10), 658-64

Jung M, Ramankulov A, Roigas J, **Johannsen M**, Ringsdorf M, Christiansen G, Jung K. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol 2007 Jun 8;8:47.

**Johannsen M**, Gneveckow U, Taymoorian K, Cho CH, Thiesen B, Scholz R, Waldöfner N, Loening SA, Wust P, Jordan A. [Thermal therapy of prostate cancer using magnetic nanoparticles]. Act Urol Esp 2007 Jun;31(6):660-7.

Jordan A, Maier-Hauff K, Wust P, Rau B, **Johannsen M**. Thermotheapie mit magnetischen Nanopartikeln. Onkologe 2007;13:894-902.

**Johannsen M**, Jordan A, Wust P, Loening SA. Re: Gommersall L, Shergill IS, Ahmed HU et al. Nanotechnology and its relevance to the urologist. Eur Urol. 2007;52:368-75. Eur Urol 2008 Apr;53(4):860.

Ramankulov A, Lein M, **Johannsen M**, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci 2008 Apr 14; [Epub ahead of print]

Fritzsche F; Wassermann W; Jung M; Tolle A; Kristiansen I; Lein M; **Johannsen M**; Dietel M; Jung K; Kristiansen G. ADAM9 is highly expressed in renal cell cancer and is associated with tumour Progression. BMC Cancer 2008, 8:179

Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, **Johannsen M**, Jung K, Kristiansen G. Identification of Stanniocalcin 2 as Prognostic Marker in Renal Cell Carcinoma. Eur Urol 2008, Apr 9. [Epub ahead of print].

Ramankulov A, Lein M, **Johannsen M**, Schrader M, Miller K, Loening SA, Jung K. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 2008 Sep 28;269(1):85-92.

**Priv. Doz.**  
**Dr. med. Manfred Johannsen**  
(F.E.B.U.)

Facharzt für Urologie  
und Andrologie  
Medikamentöse Tumorthherapie

Carl-Schurz-Str. 31  
13597 Berlin  
Tel. 030 333 4030  
Fax 030 333 1783

[www.urologie-in-spandau.de](http://www.urologie-in-spandau.de)  
[info@urologie-in-spandau.de](mailto:info@urologie-in-spandau.de)

**Johannsen M**, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V. Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicenter Retrospective Analysis; Eur Urol Oct 18. [Epub ahead of print]

Fritzsche FR, Oelrich B, **Johannsen M**, Kristiansen I, Moch H, Jung K, Kristiansen G. Claudin-1 Protein Expression is a Prognostic Marker of Patient Survival in Renal Cell Carcinomas. Clin Cancer Res 2008 Nov 1;14(21):7035-42

Roigas J, **Johannsen M**. Minimal-invasive Therapieoptionen beim Nierenzellkarzinom. Onkologe 2008; 14:1000–1012

Ficarra V, Galfano A, Cosentino M, **Johannsen M**. Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports. Eur Urol Suppl 2008 Vol. 7, 610-14

Weber A, Kristiansen I, **Johannsen M**, Oelrich B, Scholmann K, Gunia S, May M, Meyer HA, Behnke S, Moch H and Kristiansen G. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 2008, 8:369

Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermüller N, Doberstein K, Koziolk M, Fritzsche F, **Johannsen M**, Jung K, Schaidler H, Altevoigt P, Ludwig A, Pfeilschifter J, Kristiansen G. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer. 2009 Feb;45(3):478-89.

Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Pilarsky C, **Johannsen M**, Stephan C, Nietfeld W, Jung K and Kristiansen G.. Micro-RNA Profiling of Clear Cell Renal Cell Cancer identifies a highly robust Signature to define Renal Malignancy; J Cell Mol Med. 2009 Feb 17. [Epub ahead of print]

Kempkensteffen C, Hinz S, **Johannsen M**, Krause H, Magheli A, Christoph F, Köllermann J, Schrader M, Schostak M, Miller K, Weikert S. Expression of Mcl-1 Splicing Variants in Clear-Cell Renal Cancer and Their Correlation with Histopathological Parameters and Prognosis. Tumour Biol. 2009;30(2):73-9. Epub 2009 Apr 27.

Catchpole, Platzer A, Weikert C, Kempkensteffen C, **Johannsen M**, Krause Jung, Christoph F, Miller K, Willmitzer L, Selbig J, Weikert S. Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med. 2009 Oct 20. [Epub ahead of print]

Kempkensteffen C, Fritzsche FR, **Johannsen M**, Weikert S, Hinz S, Dietel M, Riener MO, Moch H, Jung K, Krause H, Miller K, Kristiansen G. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer. 2009 Aug 8;9(1):276.

Toelle A, Jung M, Lein M, **Johannsen M**, Miller K, Moch H, Jung K, Kristiansen G. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer. 2009 Jul 21;9(1):248.

**Priv. Doz.**  
**Dr. med. Manfred Johannsen**  
(F.E.B.U.)

Facharzt für Urologie  
und Andrologie  
Medikamentöse Tumorthherapie

Carl-Schurz-Str. 31  
13597 Berlin  
Tel. 030 333 4030  
Fax 030 333 1783

[www.urologie-in-spandau.de](http://www.urologie-in-spandau.de)  
[info@urologie-in-spandau.de](mailto:info@urologie-in-spandau.de)

May M, Brookman-May S, Hoschke B, Gilfrich C, Kendel F, Baxmann S, Wittke S, Kiessig ST, Miller K, **Johannsen M**. 10-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. *Cancer Immunol Immunother*. 2009 Oct 30. [Epub ahead of print]

Wille AH, **Johannsen M**, Miller K, Deger S. Laparoscopic partial nephrectomy using FloSeal for hemostasis: technique and experiences in 102 patients. *Surg Innov*. 2009 Dec;16(4):306-12. Epub 2009 Dec 22.

**Johannsen M**, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. *Int J Hyperther* 2010, im Druck

May M, Brookman-May S, Burger M, Muth CP, Gunschera J, Rogalla P, Wieland W, Hoschke B, Gilfrich C, Miller K, **Johannsen M**. Difference Between Clinical and Pathologic Renal Tumour Size, Correlation with Survival and Implications for Patient Management. *BJU Int.*, Zur Veröffentlichung eingereicht

**Johannsen M**, Staehler M, Flörcken A, Schmittl A, Ohlmann C, Otto T, Bex A, Hein P, Miller K, Weikert S, Grünwald V. Outcome of Treatment Discontinuation in Patients with Metastatic Renal Cell Carcinoma and no Evidence of Disease Following Targeted Therapy with or without Metastectomy: A Multicenter Retrospective Analysis. *Eur Urol*, Zur Veröffentlichung eingereicht

**Johannsen M**, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkenstefen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Zardi L, Berndt A, Kosmehl H, Trachsel E, Kaspar M, González-Iglesias R, Giovannoni L, Menssen HD, Neri D and de Braud F. Phase I/II Study of the Tumor-Targeting Human L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients with Advanced Renal Cell Carcinoma and other Solid Tumors. *Clin Cancer Res*, Zur Veröffentlichung eingereicht

Frey K, Schliemann C, Schwager K, Giavazzi R, **Johannsen M** and Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. *J Urol*, Zur Veröffentlichung eingereicht

**Priv. Doz.**  
**Dr. med. Manfred Johannsen**  
(F.E.B.U.)

Facharzt für Urologie  
und Andrologie  
Medikamentöse Tumorthherapie

Carl-Schurz-Str. 31  
13597 Berlin  
Tel. 030 333 4030  
Fax 030 333 1783

[www.urologie-in-spandau.de](http://www.urologie-in-spandau.de)  
[info@urologie-in-spandau.de](mailto:info@urologie-in-spandau.de)